Next, the effect of MNP anti-IL6 siRNA on hepatic thermal ablation was assessed in a second subcutaneous tumor model (MATBIII rat breast adenocarcinoma line) at 3.5d post-treatment (due to the relatively faster innate tumor growth rate, all tumors reached the mandated size for sacrifice after 3.5d) [Table 1]. This evidence concerns the gene IL6 and neoplasm.